Comparative Pharmacology
Head-to-head clinical analysis: MAREZINE versus MECLODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAREZINE versus MECLODIUM.
MAREZINE vs MECLODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Marezine (cyclizine) is a piperazine-derivative histamine H1-receptor antagonist with central anticholinergic and antiemetic activity. It competitively blocks H1 receptors in the vestibular apparatus and the chemoreceptor trigger zone (CTZ), suppressing nausea and vomiting. It also has antimuscarinic effects on the vomiting center.
Meclodium is a synthetic flavonoid derivative with antioxidant and anti-inflammatory properties. It inhibits lipid peroxidation and scavenges free radicals, protecting cell membranes from oxidative damage. It also modulates immune responses by reducing pro-inflammatory cytokine production.
50 mg intramuscularly or intravenously every 4 to 6 hours as needed for motion sickness; 50 mg orally 30 to 60 minutes before travel, then every 4 to 6 hours up to 150 mg/24h.
Not a recognized drug.
None Documented
None Documented
Terminal elimination half-life is 4-6 hours in adults; prolonged to 8-12 hours in elderly or hepatic impairment
Terminal elimination half-life is 12–15 hours in healthy adults; prolonged to 30–40 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 70-80% as unchanged drug and metabolites; fecal: ~20%; biliary: minor
Renal: 70% unchanged; Biliary/fecal: 20% as metabolites; 10% minor pathways.
Category C
Category C
Antiemetic
Antiemetic